Odylia co-founders Scott Dorman and Luk Vandenberghe speak to Xconomy about the problems keeping gene therapies for rare disease from reaching patients. In this article, Dorfman and Vandenberghe speak about the dozens, if not hundreds, of inherited retinal dystrophies that could be amenable to treatment...
Odylia will be attending the second annual Gene Therapy for Rare Disorders conference in Boston. We will be speaking to companies and individuals about how Odylia can accelerate the development of gene therapies for rare disorders. Visit Website...
Odylia Therapeutics, a new nonprofit organization, will bring treatments to clinical trial for people at risk for blindness due to ultra-rare inherited retinal diseases. By leveraging our non-profit status and world-class expertise, we will bring forward therapies for indications which have been left behind by...